Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6409639 | 0.80 | CYP3A4 (0.55) | MEN1KMT2A | |
| SCHEMBL6411610 | 0.79 | FABP7 (0.47) | FABP7FABP5CHRM2CHRM4CHRM5 | |
| SCHEMBL6409587 | 0.79 | FFAR4 (0.49) | — | |
| SCHEMBL6407755 | 0.78 | CHRM2 (0.41) | FABP7FABP5CHRM2CHRM4CHRM5 | |
| SCHEMBL6408765 | 0.78 | FABP7 (0.45) | FABP7FABP5CHRM2CHRM4CHRM5 | |
| SCHEMBL6407056 | 0.77 | CA1 (0.45) | KDM4E | |
| SCHEMBL6408113 | 0.77 | FABP7 (0.44) | FABP7FABP5CHRM2CHRM4CHRM5 | |
| SCHEMBL6409515 | 0.76 | CYP1A2 (0.39) | CHRNA7 | |
| SCHEMBL6411935 | 0.75 | ALDH1A1 (0.50) | KDM4EMEN1KMT2ACYP19A1 | |
| SCHEMBL6406983 | 0.74 | EPHX1 (0.47) | FABP7FABP5CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288526-A1 | Process for production of 2-(hydroxymethyl)cyclo-propanecarboxylic acids | SUMITOMO CHEMICAL COMPAY LIMTED (JP) | 2005-12-29 | — | — | US | disclosed |
| EP-1538141-A1 | PROCESS FOR PRODUCTION OF 2-(HYDROXYMETHYL)CYCLO- PROPANECARBOXYLIC ACIDS | Sumitomo Chemical Company, Limited (JP) | 2005-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288526-A1 | Process for production of 2-(hydroxymethyl)cyclo-propanecarboxylic acids | GRHPR, PCCA, C5 | FABP7 4846/4885FABP5 4727/4885CHRM2 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.